ARA-290 / cibinetide dosing schedule
Human schedule
ARA-290 (cibinetide) was administered subcutaneously (SubQ) once daily in studies. The figures below are generalized from published Phase 2 clinical protocols as a reference.
This is a concise reference to regimens described for adults; it is not an individual prescription.
| Period / condition | Dose | Escalation |
|---|---|---|
| Tolerance assessment | 1–2 mg subcutaneously, once daily | Starting dose |
| Main course (28 days) | 4 mg subcutaneously, once daily | Main studied dose |
| Upper studied bound | 8 mg subcutaneously, once daily | Maximum in this schedule |